SOURCE: Bioheart, Inc.

Bioheart, Inc.

December 02, 2013 12:54 ET

Bioheart Announces Agreement With StemMD to Provide Bioheart Therapies to Its Network

SUNRISE, FL--(Marketwired - Dec 2, 2013) -  Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it has entered into an agreement with StemMD. According to the agreement term sheet, StemMD will provide Bioheart therapies to its global network of physicians and qualified patients. 

"Bioheart has successfully been treating patients for a variety of conditions for almost 15 years. By combining our experiences with the regenerative network at StemMD, we will be able to provide cutting edge treatments for many indications," said Mike Tomas, CEO of Bioheart, Inc.

StemMD is a regenerative medicine company focused on techniques which include stem cell, platelet rich plasma and cytokine therapy. Through these alternative therapies, a treatment plan can be developed which is tailored to a specific disease, injury or pain. The team at StemMD has been working with a network of physicians to provide innovative therapies to patients whose experience can contribute to the development and commercialization of Bioheart's regenerative medicine products. 

About Bioheart, Inc.

Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

About StemMD

Stem MD is a healthcare network that is staffed by a team of world renowned surgeons who are experts in the area of regenerative medicine. The group only works with medical professionals who are fully trained and board certified in their field, ensuring that patients get the most advanced and effective treatment each time. The team at Stem partners with clients and healthcare workers to ensure that the care given is personalized and focused on meeting patients' needs. In addition to a high commitment to patient care and support, the therapies offered by this network are able to resolve a number of health issues, including disease and injuries. Treatments have a high rate of success, thus earning the team regular praise from patients and their caregivers, as well as frequent word of mouth recommendations. Those interested in learning more about stem cell and platelet rich plasma therapies are invited to schedule an informative consultation with a trusted, qualified professional at this facility. For more information, visit

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2012, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2013. 

Contact Information

  • Media Contact:
    Alexandra Curbelo
    Wragg & Casas Public Relations
    1221 Brickell Avenue, Suite 730
    Miami, Fl. 33131
    305-372-1234 ex.124